Dr. Scott C. Borinstein, MD
Pediatric Hematology & Oncology (Pediatric Hematology & Oncology Physician)
At a glance
- Medical school
- Virginia Commonwealth University, School of Medicine (2002)
- Years since graduation
- 24
- In the NPI registry since
- 2006
Licensed in Washington since 2005, according to the Washington State Department of Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2002Medical school: Virginia Commonwealth University, School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Hematology & Oncology Physician primary
TN license MD45386 · WA license MD00045205 (first issued 2005; expired)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Vanderbilt University Medical Center (3,567 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Payments from drug and device companies
In 2025, 2 companies reported 4 payments worth $7,031 in total to this clinician.
| Merck Sharp & Dohme LLC | $5,490 |
|---|---|
| Bayer HealthCare Pharmaceuticals Inc. | $1,541 |
| Consulting Fee | $7,031 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Dec 15, 2025 | Consulting Fee KEYTRUDA · ONCOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $1,983 |
| Merck Sharp & Dohme LLC Jun 2, 2025 | Consulting FeeCompany’s descriptionProvided as part of a clinical research engagement. | $1,830 |
| Merck Sharp & Dohme LLC Aug 11, 2025 | Consulting Fee KEYTRUDA · ONCOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $1,678 |
| Bayer HealthCare Pharmaceuticals Inc. Nov 19, 2025 | Consulting Fee Vitrakvi · Oncology | $1,541 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $15,075 in research payments for these studies, mostly to the institutions running them.
- ANBL1531 lorlatinib arm a phase 3 study of 131IMETAIODOBENZYLGUANIDINE 131IMIBG or alk inhibitor therapy added to intensive therapy for children with newly diagnosed highrisk neuroblastoma nbl
Pfizer Inc. - BAY 2731953, Prospective non-interventional study on TRK fusion cancer patients treated with larotrectinib
Bayer HealthCare Pharmaceuticals Inc. - A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearranged and or JAK Pathway Mutant Acute Lymphoblastic Leukemia
Incyte Corporation - A phase 12 study to evaluate the safety and pharmacokinetics of bosutinib in pediatric patients with cml who are resistant or intolerant to at least one prior tyrosine kinase inhibitor therapy
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.